Calico Life Sciences LLC
Clinical trials sponsored by Calico Life Sciences LLC, explained in plain language.
A research and development company focused on aging and age-related diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug combo trial launches for Hard-to-Treat tumors Results expected Oct 2026 (estimated)
-
New drug aims to shrink cysts in genetic kidney disease
Disease control Recruiting nowThis study tests an investigational drug called ABBV-CLS-628 in adults with autosomal dominant polycystic kidney disease (ADPKD), a genetic condition that causes fluid-filled cysts to grow in the kidneys. About 240 participants worldwide will receive either the drug or a placebo …
Phase 2 • Sponsor: Calico Life Sciences LLC • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug trial offers hope for rare brain disease
Disease control Recruiting nowThis study tests an experimental drug, fosigotifator, in adults and children with Vanishing White Matter disease, a rare genetic brain disorder. The main goals are to check the drug's safety and how the body processes it. About 50 participants will take the drug for up to 201 wee…
Phase 1/2 • Sponsor: Calico Life Sciences LLC • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New cancer drug combo trial launches for Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called ABBV-CLS-484, either alone or combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe and tolerable doses and to se…
Phase 1 • Sponsor: Calico Life Sciences LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC